Xiaolin Wan

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Identification of FoxM1/Bub1b signaling pathway as a required component for growth and survival of rhabdomyosarcoma
    Xiaolin Wan
    Molecular Oncology Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Cancer Res 72:5889-99. 2012
  2. pmc Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin
    X Wan
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 1928, USA
    Oncogene 28:3401-11. 2009
  3. pmc CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling
    Xiaolin Wan
    Molecular Oncology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1928, USA
    Neoplasia 8:394-401. 2006
  4. ncbi request reprint Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
    X Wan
    Molecular Oncology Section, Pediatric Oncology Branch, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, MD 20892 1928, USA
    Oncogene 26:1932-40. 2007
  5. ncbi request reprint Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma
    Xiaolin Wan
    Molecular Oncology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892 1106, USA
    Cancer Res 65:2406-11. 2005
  6. ncbi request reprint The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis
    Chand Khanna
    Pediatric Oncology Branch and Tissue Array Project Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Med 10:182-6. 2004
  7. pmc Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody
    Liang Cao
    Genetics Branch, Center for Cancer Research, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 4265, USA
    Cancer Res 68:8039-48. 2008
  8. ncbi request reprint Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival
    Emanuel F Petricoin
    Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Cellular and Gene Therapy, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Cancer Res 67:3431-40. 2007
  9. doi request reprint Targeting IGF-1R in the treatment of sarcomas: past, present and future
    Su Young Kim
    Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Bull Cancer 96:E52-60. 2009
  10. ncbi request reprint Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II-overexpressing rhabdomyosarcomas cells
    Xiaolin Wan
    Molecular Oncology Section, Pediatric Oncology Branch, NCI, National Institutes of Health, Bethesda, MD 20892 1928, USA
    Oncogene 22:8205-11. 2003

Detail Information

Publications12

  1. pmc Identification of FoxM1/Bub1b signaling pathway as a required component for growth and survival of rhabdomyosarcoma
    Xiaolin Wan
    Molecular Oncology Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Cancer Res 72:5889-99. 2012
    ..These results show the important role of the Bub1b/FoxM1 pathway in RMS and provide potential therapeutic targets...
  2. pmc Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin
    X Wan
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 1928, USA
    Oncogene 28:3401-11. 2009
    ..These data begin to integrate ezrin and beta4 integrin expression into a model of action for the mechanism of osteosarcoma metastases...
  3. pmc CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling
    Xiaolin Wan
    Molecular Oncology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1928, USA
    Neoplasia 8:394-401. 2006
    ..Together, these data suggest that CCI-779 inhibits human RMS xenograft growth by an antiangiogenic mechanism associated with the targeting of mTOR/Hif-1alpha/VEGF signaling...
  4. ncbi request reprint Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
    X Wan
    Molecular Oncology Section, Pediatric Oncology Branch, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, MD 20892 1928, USA
    Oncogene 26:1932-40. 2007
    ..Thus, combining an mTOR inhibitor and an IGF-1R antibody/inhibitor may be an appropriate strategy to enhance mTOR-targeted anticancer therapy...
  5. ncbi request reprint Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma
    Xiaolin Wan
    Molecular Oncology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892 1106, USA
    Cancer Res 65:2406-11. 2005
    ..These results suggest that blocking the mTOR/S6K1/4E-BP1 pathway may be an appropriate target for strategies to reduce tumor cell metastasis...
  6. ncbi request reprint The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis
    Chand Khanna
    Pediatric Oncology Branch and Tissue Array Project Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Med 10:182-6. 2004
    ..High ezrin expression in dog tumors was associated with early development of metastases. Consistent with this data, we found a significant association between high ezrin expression and poor outcome in pediatric osteosarcoma patients...
  7. pmc Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody
    Liang Cao
    Genetics Branch, Center for Cancer Research, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 4265, USA
    Cancer Res 68:8039-48. 2008
    ..Subsequent progression of tumors was associated with reactivation of p-AKT despite sustained suppression of IGF-IR. These results identified the first predictive biomarker for anti-IGF-IR therapies in cancer...
  8. ncbi request reprint Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival
    Emanuel F Petricoin
    Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Cellular and Gene Therapy, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Cancer Res 67:3431-40. 2007
    ..These results suggest that phosphoprotein mapping of the Akt/mTOR pathway should be studied further as a means to select patients to receive mTOR/IRS pathway inhibitors before administration of chemotherapy...
  9. doi request reprint Targeting IGF-1R in the treatment of sarcomas: past, present and future
    Su Young Kim
    Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Bull Cancer 96:E52-60. 2009
    ..In this review, we will focus on preclinical highlights in the past, current clinic trials and discuss some exciting research opportunities to foster advances in the future...
  10. ncbi request reprint Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II-overexpressing rhabdomyosarcomas cells
    Xiaolin Wan
    Molecular Oncology Section, Pediatric Oncology Branch, NCI, National Institutes of Health, Bethesda, MD 20892 1928, USA
    Oncogene 22:8205-11. 2003
    ..A better understanding of the pathway in RMS will likely contribute to insights into the biology of the RMS tumorigenesis and hopefully lead to novel therapeutic options...
  11. ncbi request reprint The biology behind mTOR inhibition in sarcoma
    Xiaolin Wan
    Molecular Oncology Section, Pediatric Oncology Branch, Building 10, Room CRC 1W 3816, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1928, USA
    Oncologist 12:1007-18. 2007
    ..Disclosure of potential conflicts of interest is found at the end of this article...
  12. pmc Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through p70 S6 kinase pathway
    Xiaolin Wan
    Molecular Oncology Section, Pediatric Oncology Branch, NCI, National Institutes of Health, Bethesda, MD 20892 1928, USA
    Neoplasia 4:400-8. 2002
    ..Thus, inhibition of the p70 S6 pathway may enhance chemotherapy-induced apoptosis in the treatment of IGF-II-overexpressing tumors...